Original filing text · Part I

Item 3 — Quantitative and Qualitative Disclosures About Market Risk

Lineage Cell Therapeutics, Inc. · 10-Q · Q2 FY2026 · Period ended Jun 30, 2026

This is the extracted source text from the SEC filing. Formatting may differ from the original document.

Under SEC rules and regulations, as a smaller reporting company, we are not required to provide the information required by this item.